Global Lung Cancer Liquid Biopsy Market 2024-2031

Global Lung Cancer Liquid Biopsy Market 2024-2031

Global Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), by Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring), by End-User (Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers), by Product (Instruments, Consumables Kits and Reagents, Software and Services) Forecast Period (2024-2031)

The lung cancer liquid biopsy market is anticipated to grow at a significant CAGR of 13.4% during the forecast period (2024-2031). Lung cancer liquid biopsy is a diagnostic technique for lung cancer detection and monitoring, using biomarkers in bodily fluids. It is minimally invasive, real-time, and provides comprehensive tumor profiling. It aids in early detection, treatment response, disease progression assessment, and therapy resistance identification. This advancement in oncology improves patient outcomes.

Market Dynamics

Rapid Advancements in Technology

Ongoing advancements in technology, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity, specificity, and accuracy of liquid biopsy assays, driving adoption in clinical practice. For instance, in December 2022, Agilent Technologies Inc. received FDA approval for Agilent Resolution ctDx FIRST as a companion diagnostic used to identify advanced non-small lung cancer in patients.

Drug Development and Clinical Trials

Globally, liquid biopsy is playing a crucial role in drug development and clinical trials by enabling the identification of biomarkers for patient selection, monitoring treatment response, and assessing drug resistance, thereby accelerating the development of targeted therapies and immunotherapies for lung cancer. The increasing funding for drug development in universities and research organizations is making a significant contribution to the growth of the global market.

Market Segmentation

Our in-depth analysis of the global lung cancer liquid biopsy market includes the following segments by type, product, and technology,

Based on biomarkers, the market is segmented into circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins

Based on application, the market is segmented into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring

Based on end-user, the market is segmented into hospitals and laboratories, specialty clinics, academic and research centers

Based on product, the market is segmented into instruments, consumables kits and reagents, software and services

Therapy Selection is Projected to Emerge as the Largest Segment

The primary factors supporting the segment's growth due to the growing trend towards personalized medicine, targeted therapy adoption, complementary to tissue biopsy, non-invasive and real-time monitoring, clinical evidence, and rapid technological advancements. Liquid biopsy allows for the identification of specific biomarkers and genetic mutations associated with each patient's tumor, enabling clinicians to tailor treatment plans based on their unique molecular profile. It also enhances the accuracy of therapy selection, particularly in cases where tissue biopsy results are inconclusive or unavailable. The increasing body of clinical evidence supporting liquid biopsy for therapy selection in lung cancer and rapid technological advancements like next-generation sequencing and digital PCR further contribute to its growth.

Regional Outlook

The global lung cancer liquid biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Holds Major Market Share

Among all the regions, North America holds a significant share owing to the presence of advanced healthcare infrastructure, strong research and development ecosystem, regulatory framework, early clinical adoption, large patient population, high disease burden, access to capital, and global leadership in biotechnology and healthcare innovation. The US and Canada have well-established regulatory frameworks for medical devices and diagnostic tests, ensuring the safety, efficacy, and quality of liquid biopsy assays. The region's culture of early adoption of medical technologies, high healthcare spending, patient demand for advanced diagnostics, and supportive reimbursement environments drive clinicians to incorporate liquid biopsy into standard cancer care protocols.

The major companies serving the global lung cancer liquid biopsy market include Eurofins Scientific, MDxHealth, CareDx, Immucor, Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Qiagen, Guardant Health, Exact Sciences Corporation, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For Instance, in July 2023, Menarini Silicon Biosystems launched its new CellSearch CTC test with the biomarker- DLL3 for the treatment of small-cell lung cancer. This launch helped the organization to expand its development of liquid biopsy assays.